110 related articles for article (PubMed ID: 22799115)
1. Shoulder X-ray--a clue to multiple myeloma.
Sharma V; Nagaraj S; Joshi VR
J Assoc Physicians India; 2012 Mar; 60():48. PubMed ID: 22799115
[No Abstract] [Full Text] [Related]
2. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Tanaka T; Yamasaki R; Omura H; Hino N
Int J Hematol; 2011 Sep; 94(3):221. PubMed ID: 21861100
[No Abstract] [Full Text] [Related]
3. Bortezomib therapy following first relapse.
Orlowski RZ;
Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
[No Abstract] [Full Text] [Related]
4. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G
Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491
[No Abstract] [Full Text] [Related]
5. Extramedullary involvement: an emerging problem in multiple myeloma.
Molica S
Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
[No Abstract] [Full Text] [Related]
6. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
7. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
[No Abstract] [Full Text] [Related]
8. Individualizing cancer therapy.
Gertz MA; Tadmor T
Leuk Lymphoma; 2010 Sep; 51(9):1585-7. PubMed ID: 20578822
[No Abstract] [Full Text] [Related]
9. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
[No Abstract] [Full Text] [Related]
10. [Bortezomib in second-line therapy].
Musch A
Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
[No Abstract] [Full Text] [Related]
11. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
[No Abstract] [Full Text] [Related]
12. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
13. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
[TBL] [Abstract][Full Text] [Related]
14. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
15. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
Zappasodi P; Dore R; Castagnola C; Astori C; Varettoni M; Mangiacavalli S; Lazzarino M; Corso A
J Clin Oncol; 2007 Aug; 25(22):3380-1. PubMed ID: 17664489
[No Abstract] [Full Text] [Related]
16. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
17. Effects of bortezomib on bone disease in multiple myeloma.
Drake MT; Rajkumar SV
Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185
[No Abstract] [Full Text] [Related]
18. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
19. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
20. Concurrent radiation therapy and bortezomib in myeloma patient.
Berges O; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
[No Abstract] [Full Text] [Related]
[Next] [New Search]
